1Hayashi K, Ando N, Watanabe H, et al. Phase II evanlu- ation of protracted infusion of eisplatin and 5-fluoroura- cil in advanced squamous cell carcinoma of the esopha- gus: a Japan Esophageal Ontology Group (JEOG) Trial (JCOG9407)[J]. Jpn J Clin Oncol, 2001, 31(9): 419-423.
2Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) ver- sus cisplatin alone in advanced squamous cell oesopha- geal cancer[J]. Eur J Cancer, 1997, 33(8): 1216-1220.
3Huang J, Zhou Y, Zhang H, et al. A phase II study of bi- weekly paclitaxel and cisplatin chemotherapy for recur- rent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy [J]. Med Oncol, 2013, 30(1): 343.
4Burkart C, Bokemeyer C, Klump B, et al. A phase II tri- al of weekly irinotecan in cisplatin-refractory esophageal cancer[J]. Anticancer Res, 2007, 27(4C): 2845-2848.
5Akutsu Y, Kono T, Uesato M, et al. S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma[J]. Ontol- ogy, 2013, 84(5): 305-310.
6Heath El, Urba S, Marshall J, et al. Phase II trial of docetaxel chemotherapy in patients with incurable adeno- carcinoma of the esophagus[J]. Invest New Drugs, 2002, 20(1): 95-99.
7Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer[J]. Ann Oncol, 2004, 15(6): 955-959.
8Shirakawa T, Kato K, Nagashima K, et al. A retrospec- tive study of docetaxel or paclitaxel in patients with ad- vanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum- based chemotherapy[J]. Cancer Chemother Pharmacol, 2014, 74(6): 1207-1215.
9Mizota A, Shitara K, Kondo C, et al. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy[J]. Oncology, 2011, 81(3-4): 237-242.
10Tanaka T, Fujita H, Sueyoshi S, et al. Second-line com- bination chemotherapy with docetaxel for cisplatin-pre- treated refractory metastatic esophageal cancer: a pre- liminary report of initial experience[J]. Chemotherapy, 2007, 53(6): 449-453.
2Ilson DH. New developments in the treatment of esophageal cancer [J]. Clin Adv Hematol Oncol, 2004, 2(2): 97-104.
3Heath EI, Urba S, Marshall J, et al. Phase I1 trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus[J]. Invest New Drugs, 2002, 20(1): 95-99.
4Cao W, Xu C, Lou G, et al. A phase U study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophagealcancer[J]. Jpn J Clin Oncol, 2009, 39(9): 582-587. DOI: 10.1093/jjeoPayp058.
5Mohammad HA, Magdy FM, Mahmoud OM. FOLFOX (oxaliplatin and 5 fiuorouracib'leucovorin) in patients with untreated metastatic gastric adenocarcinomaPhase II study[J]. Indian J Cancer, 2011, 48 (4): 460-465. DOI: 10.4103/0019-509X.92280.
6Aoyama T, Yoshikawa T, Watanabe T, et al. Safety and feasibility of S- 1 adjuvant chemotherapy for gastric cancer in elderly patients [J]. Gastric Cancer, 2012, 15(1): 76-82. DOI: 10.1007/s10120-011- 0068-7.
